Acción PTPI PETROS PHARMACEUTICALS
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Petros Pharmaceuticals

Acciones

PTPI

US71678J2096

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:30:00 06/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,692 USD -2,99 % Gráfico intradía de Petros Pharmaceuticals -1,72 % -50,92 %
23/04 Petros y Lemonaid Health colaboran para ampliar la disponibilidad de Stendra MT
23/04 Petros Pharmaceuticals, Inc. amplía la distribución en línea de STENDRA con receta a través de un nuevo acuerdo con Lemonaid Health CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA through New Agreement with Lemonaid Health
Petros, Lemonaid Health Collaborate to Expand Stendra Availability
Petros Pharmaceuticals, Inc. Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health
Petros Gets 'Positive' FDA Response Over Technology Component in Stendra OTC Process
Petros Pharmaceuticals Receives Positive Response from Fda Following Recent Demonstration of Technology Component in Pursuit of Otc Status for Stendra(R)
Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA as it Pursues OTC Status
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc
Petros Pharmaceuticals Enters into Ai Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
Thinking about buying stock in Helius Medical Technologies, Peraso, GDS Holdings, Everbridge, or Petros Pharmaceuticals?
Top Premarket Gainers
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA Rx-to-OTC Switch
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA Rx-to-OTC Switch
Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA the First Erectile Dysfunction Medication to Achieve OTC Status
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology Provider
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) the First Erectile Dysfunction Medication to Achieve OTC Status
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug Crestor's (Rosuvastatin) OTC Switch Technology Provider
Petros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción PTPI
  4. Noticias Petros Pharmaceuticals
  5. Otros idiomas